宜瑞安 INGR 深 沪
交易中 10-27 09:45:30 美东时间
118.12
0.000
0.00%
华盛通- 最 高0.00
- 今 开118.12
- 成交量 4706股
- 最 低 0.00
- 昨 收 118.12
- 总市值 75.81亿
- 52周最高 152.22
- 市盈率 静 12.16
- 换手率 0.00%
- 52周最低 118.03
- 委 比 -78.57%
- 总股本 6418.09万
- 历史最高 152.22
- 量 比 4.53
- 振 幅 0.00%
- 历史最低 7.59
- 每 手 1
- 风险率 6.68%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Demystifying Neurocrine Biosciences: Insights From 12 Analyst Reviews
In the last three months, 12 analysts have published ratings on Neurocrine Bios...
10-21 03:33
Patrick Kalotis Joins Ingredion as EVP Global Texture & Healthful Solutions
Ingredion Incorporated has appointed Patrick Kalotis as Executive Vice President of Global Texture & Healthful Solutions, effective December 1, 2025. Kalotis, who will report to CEO Jim Zallie, will lead the segment's business strategy and performance, leveraging his expertise in driving growth and innovation. Previously, Kalotis served as CEO of Tissues International North America and led the formation of Tropicana Brands Group after its separat...
10-13 13:25
美股大行评级 | 潜在涨幅4347.41%！Ascendiant Capital上调PAVmed目标价至20美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持PAVmed"买入"评级，目标价从19美元升至20美元；Ascendiant Capital：维持Plus Therapeutics"买入"评级，目标价从20.5美元升至21美元
10-07 15:04
UBS Maintains Neutral on Ingredion, Lowers Price Target to $130
UBS analyst Joshua Spector maintains Ingredion (NYSE:INGR) with a Neutral and lowers the price target from $144 to $130.
10-07 01:14
Neurocrine Biosciences' INGREZZA Demonstrates Early And Sustained Improvements In Huntington's Chorea With Good Long-Term Tolerability Over 3 Years
Once-daily INGREZZA treatment was generally well tolerated and showed early and sustained improvements in chorea severityFindings presented at 2025 MDS International Congress of Parkinson's Disease and Movement
10-06 20:38
Ingredion Announces Conditional Sale of Equity in Rafhan Maize
Ingredion Incorporated has agreed to sell a 51% stake in Rafhan Maize to Nishat Hotels and Properties Ltd. in Lahore, Pakistan, retaining a 20% ownership. The transaction, subject to international financing and regulatory approvals, is expected to close in the first half of 2026. Ingredion, headquartered in Chicago, is a global leader in ingredient solutions with $7.4 billion in annual sales and operations in nearly 120 countries.
09-29 11:03
Neurocrine Biosciences Presents New Data From Post-Hoc Analysis Of Phase 4 KINECT-PRO Open-Label Study
The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes.Post-hoc analysis from KINECT-PRO
09-23 20:35
Where Neurocrine Biosciences Stands With Analysts
14 analysts have shared their evaluations of Neurocrine Biosciences (NASDAQ:NBI...
09-22 20:02
The InterGroup Corporation Regains Compliance with Nasdaq Continued Listing Requirements
The InterGroup Corporation has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires a market value of listed securities of at least $35 million. The company was notified in November 2024 that it was not in compliance, but demonstrated compliance for 11 consecutive business days as of September 15, 2025. As a result, the matter is now closed, and its common stock will continue to be listed on The Nasdaq Capital Market under the ...
09-18 18:46
Ingredion to Webcast Investor Day on September 17
Ingredion Incorporated will host its 2025 Investor Day on September 17, 2025, featuring presentations by CEO James Zallie, CFO James Gray, and other executives. The event, which begins at 9 a.m. ET and ends around Noon ET, will include a live webcast available at [ir.ingredionincorporated.com](https://ir.ingredionincorporated.com/). Pre-registration is encouraged, and a replay will be available post-event.
09-16 10:05
